Abstract
The increasing development of novel targeted therapies for treating solid tumors has necessitated the development of technology to determine their efficacy in preclinical animal models. One such technology that can non-invasively quantify early changes in tumor cellularity as a result of an efficacious therapy is diffusion MRI. In this overview we present some theories as to the origin of diffusion changes as a result of tumor therapy, a robust methodology for acquisition of apparent diffusion coefficient maps and some applications of determining therapeutic efficacy in a variety therapeutic regimens and animal models.
Similar content being viewed by others
References
Curt GA (1994) The use of animal models in cancer drug discovery and development. Stem Cells 12(1):23–29
Crafts D, Wilson CB (1977) Animal models of brain tumors. Natl Cancer Inst Monogr 46:11–17
Peterson DL, Sheridan PJ, Brown WE Jr (1995) Animal models for brain tumors: historical perspectives and future directions. J Neurosurg 80(5):865–876
Rosenblum ML, Knebel KD, Wheeler KT, Barker M, Wilson CB (1975) Development of an in vitro colony formation assay for the evaluation of in vivo chemotherapy of a rat brain tumor. In Vitro 11(5):264–273
Rosenblum ML, Knebel KD, Vasquez DA, Wilson CB (1976) In vivo clonogenic tumor cell kinetics following 1,3-bis(2-chloroethyl)-1-nitrosourea brain tumor therapy. Cancer Res 36(10):3718–3725
Barker M, Hoshino T, Gurcay O et al. (1973) Development of an animal brain tumor model and its response to therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 33(5):976–986
Kim B, Chenevert TL, Ross BD (1995) Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative in vivo study using magnetic resonance imaging. Clin Cancer Res 1(6):643–650
Ross BD, Chenevert TL, Kim B, Ben-Joseph O (1994) Magnetic resonance imaging and spectroscopy: application to experimental neuro-oncology. Q Magn Reson Biol Med 1:89–106
Ross BD, Chenevert TL, Rehemtulla A (2002) Magnetic resonance imaging in cancer research. Eur J Cancer 38(16):2147–2156
Ross BD, Moffat BA, Lawrence TS et al. (2003) Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2(6):581–587
Stegman LD, Rehemtulla A, Hamstra DA et al. (2000) Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther 7(12):1005–1010
Zhao M, Pipe JG, Bonnett J, Evelhoch JL (1996) Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. Br J Cancer 73(1):61–64
Rehemtulla A, Hall DE, Stegman LD et al. (2002) Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging 1(1):43–55
Chenevert TL, Stegman LD, Taylor JM et al. (2000) Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 92(24):2029–2036
Chenevert TL, McKeever PE, Ross BD (1997) Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res 3(9):1457–1466
Brunberg JA, Chenevert TL, McKeever PE et al. (1995) In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol 16(2):361–371
Kauppinen RA (2002) Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy. NMR Biomed 15(1):6–17
Hakumaki JM, Poptani H, Puumalainen AM et al. (1998) Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res 58(17):3791–3799
Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ (1999) Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1(2):113–117
Chenevert TL, Meyer CR, Moffat BA et al. (2002) Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1(4):336–343
Mardor Y, Pfeffer R, Spiegelmann R et al. (2003) Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol 21(6):1094–1100
Mardor Y, Roth Y, Lidar Z et al. (2001) Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res 61(13):4971–4973
Mori S, van Zijl PC (1995) Diffusion weighting by the trace of the diffusion tensor within a single scan. Magn Reson Med 33(1):41–52
Wong EC, Cox RW, Song AW (1995) Optimized isotropic diffusion weighting. Magn Reson Med 34(2):139–143
Pipe JG, Chenevert TL (1991) A progressive gradient moment nulling design technique. Magn Reson Med 19(1):175–179
Anderson AW, Gore JC (1994) Analysis and correction of motion artifacts in diffusion weighted imaging. Magn Reson Med 32(3):379–387
Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161(2):401–407
Stejskal EO, Tanner J (1965) Spin diffusion measurements: spin-echoes in the presence of a time-dependent field gradient. J Chem Phys 42:288–292
Hamstra DA, Tychewicz JM, Lee KC et al. (2004) 19F Spectroscopy and diffusion weight MRI predict increased tumor response to cytosine deaminase and uracil phosphoribosyl transferase gene dependent enzyme prodrug therapy. Mol Ther 10(5): 916–928
Hall DE, Moffat BA, Stojanovska J et al. (2004) Therapeutic Efficacy of DTI-015 using diffusion MRI as an Early Surrogate Marker. Clin Cancer Res 10(23): 7852–7859
James K, Eisenhauer E, Christian M et al. (1999) Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 91(6):523–528
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280
Ross BD, Chenevert TL, Garwood M et al. (2003) Evaluation of (E)-2’-deoxy-2’-(fluoromethylene)cytidine on the 9L rat brain tumor model using MRI. NMR Biomed 16(2):67–76
Acknowledgments.
This work was supported by the following research grants: NIH/NCI PO1CA85878, P50CA093990, and R24CA83099
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moffat, B., Hall, D., Stojanovska, J. et al. Diffusion imaging for evaluation of tumor therapies in preclinical animal models. MAGMA 17, 249–259 (2004). https://doi.org/10.1007/s10334-004-0079-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10334-004-0079-z